Related Experiment Video
Updated: Aug 5, 2026
Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
Published on: September 10, 2014
Exosomes derived from different sources of mesenchymal stem cells attenuate cisplatin-induced ovarian toxicity
Mengtian Wei1, Hao Peng1, Haojun Tian1
1Clinical and Translational Research Center, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 200092, China.
Abstract:
Premature ovarian insufficiency (POI) poses significant challenges to reproductive health due to follicular depletion and hormonal dysregulation. Despite advances in stem cell therapy, clinical translation remains hindered by donor variability and ethical constraints. This study evaluates the therapeutic potential of exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cells (iPSCMSC-exo) versus umbilical cord-derived MSC exosomes (hUCMSC-exo) for POI intervention. In vitro, both exosome types enhanced migration and tube formation of human umbilical vein endothelial cells (HUVECs), while iPSCMSC-exo additionally promoted proliferation. iPSCMSC-exo attenuated cisplatin-induced granulosa cell apoptosis, while both types suppressed p21-mediated cell cycle arrest. In the cisplatin-induced POI mouse model, exosome treatment effectively restored Follicle-stimulating hormone (FSH) levels. However, the therapeutic efficacy of exosomes in restoring anti-Müllerian hormone (AMH) levels and follicle counts was limited, as confirmed by synchrotron radiation microtomography revealing persistent structural depletion. Notably, iPSCMSC-exo demonstrated functional outcomes similar to hUCMSC-exo. The autologous origin and scalable production of iPSCMSCs address donor heterogeneity and supply limitations inherent to traditional MSC sources. Further optimization of targeted delivery systems is warranted to overcome biodistribution challenges and enhance structural regeneration.
Insights
Induced pluripotent stem cell-derived exosomes show promise for premature ovarian insufficiency (POI) by improving hormone levels and cell function. However, structural ovarian regeneration remains a challenge, requiring further delivery system optimization.
Area of Science:
- Reproductive Biology
- Stem Cell Therapy
- Exosome Biology
Background:
- Premature ovarian insufficiency (POI) presents reproductive health challenges due to follicular depletion and hormonal imbalance.
- Current stem cell therapies for POI face limitations like donor variability and ethical concerns.
- Exosomes are emerging as cell-free therapeutic agents for various conditions.
Purpose of the Study:
- To compare the therapeutic potential of exosomes from induced pluripotent stem cell-derived mesenchymal stem cells (iPSCMSC-exo) and human umbilical cord-derived MSC exosomes (hUCMSC-exo) for treating POI.
- To evaluate the in vitro and in vivo effects of these exosomes on ovarian cells and a POI mouse model.
- To assess the feasibility of iPSCMSC-derived exosomes as an alternative to hUCMSC-derived exosomes for POI.
Main Methods:
- In vitro assays assessed exosome effects on human umbilical vein endothelial cells (HUVECs) and granulosa cells.
- A cisplatin-induced POI mouse model was used to evaluate in vivo therapeutic efficacy.
- Hormonal levels (FSH, AMH), follicle counts, and ovarian structure (synchrotron radiation microtomography) were analyzed.
Main Results:
- Both iPSCMSC-exo and hUCMSC-exo enhanced HUVEC migration and tube formation; iPSCMSC-exo also promoted proliferation.
- iPSCMSC-exo reduced granulosa cell apoptosis, and both exosome types suppressed p21-mediated cell cycle arrest.
- Exosome treatment restored Follicle-stimulating hormone (FSH) levels in the POI mouse model, but anti-Müllerian hormone (AMH) levels and follicle counts showed limited improvement, with persistent structural depletion observed.
Conclusions:
- iPSCMSC-derived exosomes offer functional benefits comparable to hUCMSC-derived exosomes in a POI model.
- The autologous nature and scalable production of iPSCMSCs address limitations of traditional MSC sources.
- Targeted delivery system optimization is crucial to enhance exosome biodistribution and ovarian structural regeneration for effective POI treatment.
